RT Journal Article
SR Electronic
T1 A multidimensional analysis reveals distinct immune phenotypes and the composition of immune aggregates in pediatric acute myeloid leukemia
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2023.03.03.23286485
DO 10.1101/2023.03.03.23286485
A1 Koedijk, Joost B.
A1 van der Werf, Inge
A1 Penter, Livius
A1 Vermeulen, Marijn A.
A1 Barneh, Farnaz
A1 Perzolli, Alicia
A1 Meesters-Ensing, Joyce I.
A1 Metselaar, Dennis S.
A1 Margaritis, Thanasis
A1 Fiocco, Marta
A1 de Groot-Kruseman, Hester A.
A1 Moeniralam, Rubina
A1 Bang Christensen, Kristina
A1 Porter, Billie
A1 Pfaff, Kathleen
A1 Garcia, Jacqueline S.
A1 Rodig, Scott J.
A1 Wu, Catherine J.
A1 Hasle, Henrik
A1 Nierkens, Stefan
A1 Belderbos, Mirjam E.
A1 Zwaan, C. Michel
A1 Heidenreich, Olaf
YR 2024
UL http://medrxiv.org/content/early/2024/07/18/2023.03.03.23286485.abstract
AB Because of the low mutational burden and consequently, fewer potential neoantigens, children with acute myeloid leukemia (AML) are thought to have a T cell-depleted or ‘cold’ tumor microenvironment and may have a low likelihood of response to T cell-directed immunotherapies. Understanding the composition, phenotype, and spatial organization of T cells and other microenvironmental populations in the pediatric AML bone marrow (BM) is essential for informing future immunotherapeutic trials about targetable immune-evasion mechanisms specific to pediatric AML. Here, we conducted a multidimensional analysis of the tumor immune microenvironment in pediatric AML and non-leukemic controls. We demonstrated that nearly one-third of pediatric AML cases has an immune-infiltrated BM, which is characterized by a decreased ratio of M2-to M1-like macrophages. Furthermore, we detected the presence of large T cell networks, both with and without colocalizing B cells, in the BM and dissected the cellular composition of T- and B cell-rich aggregates using spatial transcriptomics. These analyses revealed that these aggregates are hotspots of CD8+ T cells, memory B cells, plasma cells and/or plasmablasts, and M1-like macrophages. Collectively, our study provides a multidimensional characterization of the BM immune microenvironment in pediatric AML and indicates starting points for further investigations into immunomodulatory mechanisms in this devastating disease.Competing Interest StatementJ.S.G. reports serving on steering committee and receiving personal fees from AbbVie, Genentech, and Servier and institutional research funds from AbbVie, Genentech, Pfizer, and AstraZeneca. S.R. receives research support from Bristol-Myers-Squibb and KITE/Gilead, and is a member of the SAB of Immunitas Therapeutics. C.J.W. holds equity in BioNTech, Inc and receives research support from Pharmacyclics. C.M.Z. receives institutional research support from Pfizer, Abbvie, Takeda, Jazz, Kura, Gilead, and Daiichi Sankyo, provides consultancy services for Kura, Bristol-Myers-Squibb, Novartis, Gilead, Incyte, and Syndax, and serves on advisory committees for Novartis, Sanofi, and Incyte. O.H. receives institutional research support from Syndax and Roche. The remaining authors declare no competing financial interests. Funding StatementThis work has been funded in part by a KIKA (329) program grant to O.H. L.P. is a Scholar of the American Society of Hematology, participant in the BIH Charite Digital Clinician Scientist Program funded by the DFG, the Charite Universitatsmedizin Berlin, and the Berlin Institute of Health at Charite (BIH) and is supported by the Max-Eder program of the German Cancer Aid. J.S.G. is supported by the Conquer Cancer Foundation Career Development Award, Leukemia and Lymphoma Society Translational Research Program Award, and NIH K08CA245209. NCI CTEP provided study drug (Ipilimumab) support. This work was supported by National Institutes of Health, National Cancer Institute grant P01CA229092 (C.J.W.), UM1CA186709 (Principal Investigator: Geoffrey Shapiro), National Cancer Institute Cancer Therapy Evaluation Program, Bristol-Myers Squibb, and LLS Therapy Accelerator Program. This work was further supported by the CIMAC-CIDC Network. Scientific and financial support for the CIMAC-CIDC Network is provided through National Institutes of Health, National Cancer Institute Cooperative Agreements U24CA224319 (to the Icahn School of Medicine at Mount Sinai CIMAC), U24CA224331 (to the Dana-Farber Cancer Institute CIMAC), U24CA224285 (to the MD Anderson Cancer Center CIMAC), U24CA224309 (to the Stanford University CIMAC), and U24CA224316 (to the CIDC at Dana-Farber Cancer Institute). The CIMAC-CIDC website is found at https://cimac-network.org/. Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:This study complies with all relevant ethical regulations and was approved by the Institutional Review Boards of the Princess Maxima Center for Pediatric Oncology (PMCLAB2021.207 & PMCLAB2021.238), the Scientific Committee of the Dutch Nationwide Pathology Databank (PALGA: lzv2021-82)64 and at participating sites of the ETCTN/CTEP 10026 study after written informed consent was obtained. All patients treated at the Princess Maxima Center, Aarhus University Hospital, and Dana-Farber Cancer Institute provided written consent for banking and research use of these specimens, according to the Declaration of Helsinki. BM biopsy tissues acquired from external biobanks (n=28) were leftover material from standard care procedures and therefore, no informed consent was acquired, according to Dutch legislation and the code of conduct of the Committee on Regulation of Health Research (COREON).I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.YesSequencing data can be accessed from the Gene Expression Omnibus (nCounter data: GSEXXX; GeoMx data: GSEXXX; both normalized counts [GSE IDs will be available upon approval]) and from the European Genome-phenome Archive (EGA) database (https://ega-archive.org/studies/EGAXXX; raw nCounter and GeoMx data [idem]).